Biomedcode is in search of a motivated Research and Business Manager to join the team and lead strategic initiatives focused on drug discovery projects. S/he will focus on identifying and pursuing grant funding and investment opportunities, managing intellectual property (IP) portfolios and liaising with potential stakeholders. The ideal candidate will lead initiatives to generate and engage with business partners to exploit the company’s IP portfolio. Critical thinking and a demonstrated ability to execute a particular IP exploitation strategy, identify partnerships and financing opportunities in the life sciences industry as well as develop and manage IP commercialization strategies are required.
Extending on our previous work on the treatment of arthritis with combination therapies of dasatinib with subtherapeutic doses of anti-TNF biologics, we explore here in this collaborative research project the interplay of inflammation and senescence in the context of combination treatments.
Published in Mechanisms of Ageing and Development 2023, 214, 111856.
In the frame of a collaborative project co-financed by the European Union and Greek national funds (BreastCaRANKL project code: T1EDK-02829), Biomedcode has collaborated with Dr. Douni’s lab at BSRC Al. Fleming and the companies Bioemtech and Protavio to develop an innovative human-RANKL dependent breast cancer mouse model aiming to study RANKL dependent breast cancer mechanisms and to establish novel integrated preclinical platforms with modules of advanced imaging and molecular analysis for the evaluation of human therapeutics targeting cancer.
Published in Cancers 2023, 15(15), 4006.
Read More
In the frame of a collaborative drug development project scientists from Biomedcode and BSRC Al. Fleming using bioinformatics tools, have repurposed the neuroleptic drug amisulpride for the reversal of the pathogenic expression signature of synovial fibroblasts and the treatment of arthritis pathology.
Published in JCI Insight 2023 May 8;8(9):e165024. doi: 10.1172/jci.insight.165024.
In this paper the anti-TNF/IL6 bispecific nanobody is tested on the Tg197 arthritis model.
Published in Science Translational Medicine 2023 Feb;15(681):eabq4419. doi: 10.1126/scitranslmed.abq4419.
Biomedcode scientists have coauthored a paper published in Scientific Reports that provides for the first time a possible mechanistic explanation to the growth retardation commonly observed in children with chronic inflammatory diseases treated with glucocorticoids. The Tg197 human TNF transgenic mice were used as a tool to show that TNF overexpression and dexamethasone treatment impair bone growth separately and in an additive manner.
Published in Scientific Reports 2022 Oct 28;12(1):18189. doi: 10.1038/s41598-022-22734-8
Biomedcode is in search of an individual or company with proven experience in Intellectual Property exploitation to take over the management of the IP of its drug discovery projects. The ideal candidate will lead initiatives to generate and engage with business partners to exploit the company’s IP portfolio. Critical thinking and a demonstrated ability to execute a particular IP exploitation strategy, identify partnerships and financing opportunities in the life sciences industry as well as develop and manage IP commercialization strategies are required.
Biomedcode is pleased to announce that, the T2EDK program -development of a bronchoscopic biopsies-on-chip (BioOnChip) platform for immunotherapy drug screening in non-small cell lung cancer- initiated in collaboration with the BSRC Al. Fleming researcher M. Tsoumakidou, the Department of Computer Science and Biomedical Informatics of the University of Thessaly and the Pulmonary Clinic of the University of Ioannina has been financed by the European Union – Next Generation EU and the National Recovery and Resilience Plan Greece 2.0 funds. BioOnChip aims to explore the applicability of an innovative 3D microfluidic microculture, i.e. tumor-on-chip, in predicting real-time responses to PD1-blockade in NSCLC patients, that, if efficient, might have important socioeconomic impact.
INFRAFRONTIER has achieved two major milestones in the first half of 2024, with two collaborative projects being funded by the European Commission INFRAPLUS and PRIMTECH3R
Biomedcode participates in both projects together with other partners and collaborators:
Helmholtz Munich – ERA-LEARN – Institut Clinique De La Souris ICS – CIPHE – Centre d’Immunophénomique – University of Oulu – Karolinska Institutet – CSIC – Centro Nacional de Biotecnología (CNB-CSIC) – Consiglio Nazionale delle Ricerche – Vetmeduni – BSRC Alexander Fleming – Universitat Autònoma de Barcelona – UK Research and Innovation – Mary Lyon Centre at MRC Harwell – MRC National Mouse Genetics Network – Biomedcode – AKITA, by Finnadvance – CNRS – Calouste Gulbenkian Foundation Instituto Gulbenkian de Ciencia – The Netherlands Cancer Institute – Antoni van Leeuwenhoek – The Hospital for Sick Children – Institute of Molecular Genetics of the Czech Academy of Sciences – Czech Centre for Phenogenomics – UMCG research – EMBL – INSERM and Aarhus University